Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Source updated2025-12-23Last update listed in the registry record
Version history
Changes to this trial
Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
· 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Toassesslong-termsafetyina multicenter, open-label, single-arm, 52-week study in subjects with atopic dermatitis treated with ARQ-151 cream: AEs and SAEs
+ After
Measure: Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE)
Trial